Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology,Hematology
Reference13 articles.
1. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study;Pappas;Cancer Chemother Pharmacol,2005
2. Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571;Kitiyakara;Nephrol Dial Transplant,2002
3. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia;Pou;Leuk Lymphoma,2003
4. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer;Foringer;Ann Pharmacother,2005
5. Partial Fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss;Francois;Am J Kidney Dis,2008
Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Improvement in Dasatinib-Induced Proteinuria after Switching to Nilotinib: A Case Report;The Korean Journal of Medicine;2023-06-01
2. Peptides GWN and GW protect kidney cells against Dasatinib induced mitochondrial injury in a SIRT1 dependent manner;Food Chemistry: Molecular Sciences;2022-07
3. Nephrotoxicity From Molecularly Targeted Chemotherapeutic Agents;Advances in Chronic Kidney Disease;2021-09
4. Dasatinib mitigates renal fibrosis in a rat model of UUO via inhibition of Src/STAT-3/NF-κB signaling;Environmental Toxicology and Pharmacology;2021-05
5. The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia;Internal Medicine;2020-11-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3